Latest News, Press Releases & Events

SPX-101 is Stable In and Retains Function After Exposure to Cystic Fibrosis Sputum

The science team at Spyryx has recently published an open-access article in the Journal of Cystic Fibrosis, supporting the stability of SPX-101 in the protease-rich environment of cystic fibrosis airways. Here, we demonstrate SPLUNC1, the natural allosteric regulator of ENaC, is degraded by multiple proteases present in sputum of CF patients. SPX-101 is stable in […]

Continue Reading

Phase 2 Study Shows Promising Results for Potential Mucus Clearance Drug

A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells. – Published on June 7, 2018 | Cystic Fibrosis Foundation® News A new […]

Continue Reading

Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibrosis via Novel Modulation of ENaC

Inhaled drug can be used regardless of a patient’s particular CF mutation. – DURHAM, N.C., June 6, 2018 /PRNewswire/ — Today Spyryx shared positive data for the first cohort of the SPX-101 Phase 2 clinical trial HOPE-1 (Hydration for Optimal Pulmonary Effectiveness), which showed that treatment with SPX-101 in patients with cystic fibrosis (CF) resulted […]

Continue Reading